AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pradines, B.
Right arrow Articles by Rogier, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pradines, B.
Right arrow Articles by Rogier, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2006, p. 3225-3226, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00777-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

In Vitro Activity of Tafenoquine against the Asexual Blood Stages of Plasmodium falciparum Isolates from Gabon, Senegal, and Djibouti


   LETTER
Top
 Letter
References
 
Antimalarial drugs, when used as monotherapies, are rapidly losing their effectiveness. One promising new drug is the antimalarial 8-aminoquinoline tafenoquine (SB-252263 [formerly WR-238605]), a new synthetic primaquine analogue codeveloped by the U.S. Army and GlaxoSmithKline, which has been shown effective not only against the liver stages, gametocytes, and sporozoites of Plasmodium falciparum (4), but also against the blood stages of the parasite (13). Tafenoquine demonstrated significant protection against P. falciparum infection in Gabon, Ghana, and Kenya (6, 7, 12). Tafenoquine has been reported to be well tolerated, with only mild gastrointestinal effects (8).

Isolates were collected in 1999 from malaria patients from Libreville (Gabon, Central Africa), Dielmo and Ndiop (Senegal, West Africa), and Djibouti (East Africa). The isotopic, microdrug susceptibility test used was described previously (10).

The 50% inhibitory concentration (IC50) values for tafenoquine were in the range 0.9 to 9.7 µM in Djibouti, 0.6 to 33.1 µM in Gabon, and 0.5 to 20.7 µM in Senegal. The geometric mean IC50 was 2.68 µM in Djibouti, versus 4.62 µM in Gabon and 5.06 µM in Senegal (Table 1). Tafenoquine was found to possess marked blood schizonticidal activity in P. falciparum in areas with high percentages of multidrug-resistant parasite populations. There was no difference in the tafenoquine mean IC50 values between Dielmo-Ndiop and Libreville, even though the levels of reduced susceptibility for chloroquine, mefloquine, cycloguanil, and pyrimethamine were different. Conversely, tafenoquine was significantly more active in Djibouti than in Gabon or Senegal (P = 0.016). The results of these in vitro tests were comparable with those reported by other authors in culture-adaptated P. falciparum clones and strains (2, 11).


View this table:
[in this window]
[in a new window]
  		TABLE 1. In vitro susceptibilities and prevalence of resistance or reduced susceptibility of wild isolates of Plasmodium falciparum from Djibouti, Gabon, and Senegal to the drugs shown

 
Published in vitro data for the blood schizonticidal activity of primaquine in P. falciparum show a range of IC50 values between 0.3 µM and 14 µM (1, 2, 13). In this study, there was no difference in the tafenoquine mean IC50 values between the three areas (P = 0.111). Tafenoquine is more active in vitro than primaquine, wherever the area. Tafenoquine exerts a blood schizonticidal activity 4 to 100 times higher than that of primaquine in the Plasmodium berghei and Plasmodium yoelii mouse model (9). Tafenoquine had a half-life that is more than 50 times longer than that of primaquine (3, 5). The difference in kinetics results in more prolonged, high concentrations of tafenoquine in the blood. These properties permit weekly dosing for prophylaxis and short-term or single-dose therapy for radical cure.

Only 3.5% of the variation of response to tafenoquine is explained by response variation to primaquine. The coefficients of determination, r2, ranging from 0.001 to 0.113, are too weak to consider that cross-resistance may exist between tafenoquine and standard antimalarial drugs. Since correlation analysis provides an insight into the mode of action and cross-susceptibilities between different drugs, these data may be seen as an indication of the relative independence of tafenoquine from the susceptibility of P. falciparum to standard antimalarial drugs.

In conclusion, these data permit definition of the baseline of in vitro susceptibility to tafenoquine before its use and will allow the monitoring of its resistance or its reduced susceptibility when tafenoquine will be commonly used. Given its greater schizonticidal activity, tafenoquine is a promising candidate as a short treatment for P. falciparum and Plasmodium vivax malaria. However, the potential side effects of tafenoquine, such as the production of methemoglobin and the risk of hemolysis in glucose-6-phosphate dehydrogenase-deficient patients, have to be taken into consideration (14).


   ACKNOWLEDGMENTS
 
The authors thank for their participation the populations and medical staffs of Libreville, Dielmo, Ndiop, and Djibouti. We thank W. K. Milhous from the Walter Reed Army Institute of Research and S. Duparc and the members of the tafenoquine project team (GlaxoSmithKline) for a critical reading of this letter.

This work was supported by the Délégation Générale pour l'Armement (grant 03CO001, no. 010808/03-6) and the Direction Centrale du Service de Santé des Armées.

The authors have no conflicts of interest concerning the work reported in this letter. The authors do not own stocks or shares in a company that might be financially affected by the conclusions of this article. The conclusions of this article were not financially affected.


   REFERENCES
Top
 Letter
 References
 

  1. Basco, L. K., J. Bickii, and P. Ringwald. 1999. In vitro activity of primaquine against the asexual blood stage of Plasmodium falciparum. Ann. Trop. Med. Parasitol. 93:179-182.[CrossRef][Medline]
  2. Bray, P. G., S. Deed, E. Fox, M. Kalkanidis, M. Mungthin, L. W. Deady, and L. Tilley. 2005. Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. Biochem. Pharmacol. 70:1158-1166.[CrossRef][Medline]
  3. Brueckner, R. P., K. C. Lasseter, E. T. Lin, and B. G. Schuster. 1998. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am. J. Trop. Med. Hyg. 58:645-649.[Abstract]
  4. Coleman, R. E., A. M. Clavin, and W. K. Milhous. 1992. Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR mice and Anopheles stephensi mosquitoes. Am. J. Trop. Med. Hyg. 46:169-182.[Abstract/Free Full Text]
  5. Edstein, M. D., D. A. Kocisko, T. G. Brewer, D. S. Walsh, C. Eamsila, B. G. Charles, and K. H. Rieckmann. 2003. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis. Clin. Infect. Dis. 37:1654-1658.[CrossRef][Medline]
  6. Hale, B. R., S. Owusu-Agyei, D. J. Fryauff, K. A. Koram, A. R. Oduro, W. R. Prescott, J. K. Baird, F. Nkrumah, T. L. Ritchie, E. D. France, F. N. Binka, J. Horton, and S. L. Hoffman. 2003. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin. Infect. Dis. 36:541-549.[CrossRef][Medline]
  7. Lell, F., J. F. Faucher, M. Anoumou Missinou, S. Borrmann, O. Dangelmaier, and J. Horton. 2000. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 355:2041-2045.[CrossRef][Medline]
  8. Nasveld, P., S. Kitchener, M. Edstein, and K. Rieckmann. 2002. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax in Australian Defense Force personnel. Trans. R. Soc. Trop. Med. Hyg. 96:683-684.[CrossRef][Medline]
  9. Peters, W., and B. L. Robinson. 1993. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238605. Ann. Trop. Med. Parasitol. 87:547-552.[Medline]
  10. Pradines, B., A. Tall, F. Ramiandrasoa, A. Spiegel, T. Fusai, J. Mosnier, W. Daries, J. F. Trape, G. Kunesch, D. Parzy, and C. Rogier. 2006. Compounds with iron chelating effects for treatment of Plasmodium falciparum infections. In vitro activity against Senegalese isolates and comparison with standard antimalarial drugs. J. Antimicrob. Chemother. 57:1093-1099.[Abstract/Free Full Text]
  11. Russel, B. M., R. Udomsangpetch, K. H. Rieckmann, B. M. Kotecka, R. E. Coleman, and J. Sattabongkot. 2003. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 47:170-173.[Abstract/Free Full Text]
  12. Shanks, G. D., A. J. Oloo, G. M. Aleman, C. Ohrt, F. W. Klotz, D. Braitman, J. Horton, and R. Brueckner. 2001. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin. Infect. Dis. 33:1968-1974.[CrossRef][Medline]
  13. Vennerstrom, J. L., E. O. Nuzum, R. E. Miller, A. Dorf, L. Gerena, P. A. Dande, W. Y. Ellis, R. G. Ridley, and W. K. Milhous. 1999. 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob. Agents Chemother. 43:598-602.[Abstract/Free Full Text]
  14. Wernsdorfer, W. H. 2000 Tafanoquine. Curr. Opin. Antiinfective Investig. Drugs 2:88-98.
Bruno Pradines*
Unité de Recherche en Biologie et Epidémiologie Parasitaires
Institut de Médecine Tropicale du Service de Santé des Armées
Le Pharo, 13998 Marseille, France

Modeste Mabika Mamfoumbi
Département de Parasitologie-Mycologie
Faculté de Médecine
Université des Sciences de la Santé
Libreville, Gabon,1

Adama Tall
Service d'Epidémiologie
Institut Pasteur
Dakar, Sénégal,2

Cheikh Sokhna
Unité de Recherche 077 de Paludologie Afrotropicale
Institut pour la Recherche et le Développement
Dakar, Sénégal,3

Jean-Louis Koeck
Service de Biologie Médicale
Centre Hospitalier des Armées Bouffard
Djibouti,4

Thierry Fusai
Joel Mosnier
Unité de Recherche en Biologie et Epidémiologie Parasitaires
Institut de Médecine Tropicale du Service de Santé des Armées
Le Pharo, 13998 Marseille, France,5

Eric Czarnecki
Service de Biologie Médicale
Centre Hospitalier des Armées Bouffard
Djibouti,6

André Spiegel
Service d'Epidémiologie
Institut Pasteur
Dakar, Sénégal,7

Jean-François Trape
Unité de Recherche 077 de Paludologie Afrotropicale
Institut pour la Recherche et le Développement
Dakar, Sénégal,8

Maryvonne Kombila
Département de Parasitologie-Mycologie
Faculté de Médecine
Université des Sciences de la Santé
Libreville, Gabon,9

Christophe Rogier
Unité de Recherche en Biologie et Epidémiologie Parasitaires
Institut de Médecine Tropicale du Service de Santé des Armées
Le Pharo, 13998 Marseille, France,10

* Phone: 33 4 91 15 01 10, Fax: 33 4 91 15 01 64, E-mail: bruno.pradines{at}free.fr

Antimicrobial Agents and Chemotherapy, September 2006, p. 3225-3226, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00777-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pradines, B.
Right arrow Articles by Rogier, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pradines, B.
Right arrow Articles by Rogier, C.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS